

# Release Notes for the TJC2021B2 Manual

## Measure Information Forms

Section	Rationale	Description
IMM-2	<p>The included population list for Influenza Immunization (IMM-2) has been updated to align with the CDC's recommendation to defer influenza vaccination for hospitalized, symptomatic COVID-19 patients.</p> <p>Added updated reference for COVID-19 patients.</p>	<p>Included Population List</p> <p><b>Change From:</b></p> <ul style="list-style-type: none"> <li>Patients who have an allergy/sensitivity to the influenza vaccine, anaphylactic latex allergy or anaphylactic allergy to eggs, or for whom the vaccine is not likely to be effective because of bone marrow transplant within the past 6 months, or history of Guillian-Barre syndrome within 6 weeks after a previous influenza vaccination</li> </ul> <p><b>Change To:</b></p> <ul style="list-style-type: none"> <li>Patients who have an allergy/sensitivity to the influenza vaccine, anaphylactic latex allergy or anaphylactic allergy to eggs, or for whom the vaccine is not likely to be effective because of bone marrow transplant within the past 6 months, or history of Guillian-Barre syndrome within 6 weeks after a previous influenza vaccination, or symptomatic suspected or confirmed COVID-19</li> </ul> <p><b>Added the following reference to the Selected References section:</b></p> <ul style="list-style-type: none"> <li>Grohskopf LA, Alyanak E, Ferdinands JM, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021–22 Influenza Season. MMWR Recomm Rep 2021;70(No. RR-5):1–28. DOI: <a href="http://dx.doi.org/10.15585/mmwr.rr7005a1">http://dx.doi.org/10.15585/mmwr.rr7005a1</a></li> </ul>

## Data Elements

Section	Rationale	Description
Influenza Vaccination Status	The measure data element Influenza Vaccination Status allowable value 4, has been updated to align with the CDC’s recommendation to defer influenza vaccination for hospitalized, symptomatic COVID-19 patients.	<p>Allowable Values:</p> <p><b>Change From:</b></p> <p>4 There was documentation of an allergy/sensitivity to influenza vaccine, anaphylactic latex allergy or anaphylactic allergy to eggs OR is not likely to be effective because of bone marrow transplant within the past 6 months OR history of Guillian-Barré syndrome within 6 weeks after a previous influenza vaccination.</p> <p><b>Change To:</b></p> <p>4 There was documentation of an allergy/sensitivity to influenza vaccine, anaphylactic latex allergy or anaphylactic allergy to eggs OR is not likely to be effective because of bone marrow transplant within the past 6 months OR history of Guillian-Barré syndrome within 6 weeks after a previous influenza vaccination OR symptomatic suspected or confirmed COVID-19.</p>

## Supplemental Materials

Section	Rationale	Description
<i>No Supplemental Material release notes for the TJC2021B2 release.</i>		